3.8 Article

The descriptive epidemiology of DSM-IV Adult ADHD in the World Health Organization World Mental Health Surveys

出版社

SPRINGER WIEN
DOI: 10.1007/s12402-016-0208-3

关键词

ADHD; Attention-deficit/hyperactivity disorder; Comorbidity; Disability epidemiology; Impairment; Prevalence; Treatment

资金

  1. National Institute of Mental Health (NIMH) [R01 MH070884, U01-MH60220]
  2. John D. and Catherine T. MacArthur Foundation
  3. Pfizer Foundation
  4. US Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]
  5. Fogarty International Center [FIRCA R03-TW006481]
  6. Pan American Health Organization
  7. Eli Lilly and Company
  8. Ortho-McNeil Pharmaceutical
  9. GlaxoSmithKline
  10. Bristol-Myers Squibb
  11. Ministry of Social Protection
  12. Center for Excellence on Research in Mental Health (CES University)
  13. Secretary of Health of Medellin
  14. European Commission [QLG5-1999-01042, SANCO 2004123, EAHC 20081308]
  15. Piedmont Region (Italy)
  16. Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Spain [FIS 00/0028]
  17. Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]
  18. Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III [CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]
  19. Japanese through United Nations Development Group Iraq Trust Fund (UNDG ITF)
  20. European Funds through United Nations Development Group Iraq Trust Fund (UNDG ITF)
  21. Lebanese Ministry of Public Health
  22. WHO (Lebanon)
  23. National Institute of Health / Fogarty International Center [R03 TW006481-01]
  24. Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences
  25. AstraZeneca
  26. Eli Lilly
  27. Hikma Pharmaceuticals
  28. Janssen-Cilag
  29. Lundbeck
  30. Novartis
  31. Servier
  32. National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280]
  33. National Council on Science and Technology (CONACyT) [G30544-H]
  34. Health & Social Care Research & Development Division of the Public Health Agency
  35. National Institute of Health of the Ministry of Health of Peru
  36. EEA Financial Mechanism [PL 0256]
  37. Norwegian Financial Mechanism
  38. Polish Ministry of Health
  39. Champalimaud Foundation
  40. Gulbenkian Foundation
  41. Foundation for Science and Technology (FCT)
  42. Ministry of Health
  43. Ministry of Public Health
  44. Regional Health Authorities of Murcia (Servicio Murciano de Salud and Consejeria de Sanidad y Politica Social)
  45. Fundacion para la Formacion e Investigacion Sanitarias (FFIS) of Murcia
  46. Shenzhen Bureau of Health
  47. Shenzhen Bureau of Science, Technology, and Information
  48. State of Sao Paulo Research Foundation (FAPESP) [03/00204-3]
  49. Substance Abuse and Mental Health Services Administration (SAMHSA)
  50. Robert Wood Johnson Foundation (RWJF) [044708]
  51. John W. Alden Trust
  52. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [03/00204-3] Funding Source: FAPESP

向作者/读者索取更多资源

We previously reported on the cross-national epidemiology of ADHD from the first 10 countries in the WHO World Mental Health (WMH) Surveys. The current report expands those previous findings to the 20 nationally or regionally representative WMH surveys that have now collected data on adult ADHD. The Composite International Diagnostic Interview (CIDI) was administered to 26,744 respondents in these surveys in high-, upper-middle-, and low-/lower-middle-income countries (68.5% mean response rate). Current DSM-IV/CIDI adult ADHD prevalence averaged 2.8% across surveys and was higher in high (3.6%)- and upper-middle (3.0%)- than low-/lower-middle (1.4%)-income countries. Conditional prevalence of current ADHD averaged 57.0% among childhood cases and 41.1% among childhood subthreshold cases. Adult ADHD was significantly related to being male, previously married, and low education. Adult ADHD was highly comorbid with DSM-IV/CIDI anxiety, mood, behavior, and substance disorders and significantly associated with role impairments (days out of role, impaired cognition, and social interactions) when controlling for comorbidities. Treatment seeking was low in all countries and targeted largely to comorbid conditions rather than to ADHD. These results show that adult ADHD is prevalent, seriously impairing, and highly comorbid but vastly under-recognized and undertreated across countries and cultures.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据